文献速递生殖医学

重组人血管内皮生长因子对青春期前男孩睾丸组织异种移植的影响:一项三例研究

Effect of recombinant human vascular endothelial growth factor on testis tissue xenotransplants from prepubertal boys: a three-case study.
PubMed 文献 · Reprod Biomed Online · 2019-03-12

研究探讨重组人血管内皮生长因子(VEGF-165)能否提高人未成熟睾丸组织(ITT)异种移植效率。三例青春期前男孩的ITT片段经VEGF-165或对照培养5天后移植至免疫缺陷小鼠睾丸,移植后4个月和9个月评估血管化、生精小管完整性和生殖细胞。两例供体VEGF处理移植物的血管表面和血管密度更高、完整生精小管更多,精原细胞随时间增加更明显;第三例供体因活检前已接受环孢素治疗而未能回收移植物。作者建议未来可考虑将VEGF作为提高未成熟睾丸组织移植效率的因子。

要点

  • VEGF处理的两例供体移植物血管表面(P=0.004)和血管密度(P=0.011)高于对照。
  • VEGF处理组完整生精小管随时间增多(P=0.039),精原细胞增加更明显(P=0.020)。
  • 9个月时各处理组均可见精母细胞;第三例供体移植物未能回收。

核心结论

  • 三例中两例显示VEGF预处理改善移植血管化,进而改善生精小管完整性和精原细胞存活。
  • 作者认为虽需进一步研究,但建议未来可考虑将VEGF作为提高未成熟睾丸组织移植效率的因子。

研究设计与样本

  • 三例青春期前男孩的未成熟睾丸组织片段,经VEGF-165或对照培养5天后异种移植至免疫缺陷小鼠睾丸。
  • 移植后4个月和9个月回收移植物,用组织学和免疫组化评估血管化、生精小管完整性、精原细胞数和生殖细胞分化。

主要发现

  • 供体1和供体2的VEGF处理移植物总体血管表面高于对照(P=0.004),血管密度高于对照(P=0.011)。
  • VEGF处理移植物随时间含有更多完整生精小管(P=0.039)。
  • 精原细胞数随时间增加(P<0.001),与处理和供体无关;VEGF处理移植物随时间增加更明显(P=0.020)。
  • 9个月时异种移植物中存在精母细胞,与处理无关。
  • 供体3因活检前已接受环孢素治疗再生障碍性贫血,未能回收任何移植物。

临床怎么用

  • 作者建议未来可考虑将VEGF作为提高未成熟睾丸组织移植效率的因子,但指出需进一步研究。

局限性

  • 作者指出需进一步研究(further studies are warranted)。
  • 三例中仅两例显示VEGF改善移植血管化。
  • 供体3因活检前已接受环孢素治疗再生障碍性贫血而未能回收移植物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does recombinant human vascular endothelial growth factor (VEGF-165) improve the efficiency of human immature testis tissue (ITT) xenotransplantation? DESIGN: ITT fragments from three prepubertal boys were cultured for 5 days with VEGF-165 or without (control) before xenotransplantation into the testes of immunodeficient mice. Xenotransplants were recovered at 4 and 9 months post-transplantation and vascularization, seminiferous tubule integrity, number of spermatogonia and germ cell differentiation were evaluated by histology and immunohistochemistry. RESULTS: Transplants from donor 1 and donor 2 treated with VEGF demonstrated higher vascular surface (P = 0.004) and vessel density (P = 0.011) overall and contained more intact seminiferous tubules (P = 0.039) with time, compared with controls. The number of spermatogonia was increased over time (P < 0.001) irrespective of treatment and donor, whereas, for the VEGF-treated transplants, the increase was even higher over time (P = 0.020). At 9 months, spermatocytes were present in the xenotransplants, irrespective of treatment. No transplants could be recovered from donor 3, who had already received treatment with cyclosporine for aplastic anaemia before biopsy. CONCLUSIONS: In-vitro pre-treatment of human prepubertal testis tissue with VEGF improved transplant vascularization in two out of three cases, resulting in improved seminiferous tubule integrity and spermatogonial survival during xenotransplantation. Although further studies are warranted, we suggest VEGF to be considered as a factor for improving the efficiency of immature testis tissue transplantation in the future.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Ntemou E, Kadam P, Van Laere S, et al. Effect of recombinant human vascular endothelial growth factor on testis tissue xenotransplants from prepubertal boys: a three-case study. Reprod Biomed Online. 2019. PMID: 31005581. doi:10.1016/j.rbmo.2019.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。